Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clinigen Group plc stock logo
CLIGF
Clinigen Group
$8.02
$8.02
$8.02
$11.56
$1.07B0.498,620 shsN/A
Capstone Mining Corp. stock logo
CSFFF
Capstone Mining
$5.86
$2.82
$6.19
N/AN/AN/A21,800 shs
Elementis plc stock logo
ELMTY
Elementis
$7.48
$7.53
$4.85
$7.58
$1.10B142 shsN/A
Li & Fung Limited stock logo
LFUGY
Li & Fung
$0.22
-6.5%
$0.22
$0.13
$0.36
$958.49M0.3817,949 shs1,000 shs
Oxford Biomedica plc stock logo
OXBDF
Oxford Biomedica
$2.82
+3.7%
$2.46
$2.09
$6.02
$271.45M1.153,364 shs400 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clinigen Group plc stock logo
CLIGF
Clinigen Group
0.00%0.00%0.00%0.00%0.00%
Capstone Mining Corp. stock logo
CSFFF
Capstone Mining
0.00%0.00%0.00%0.00%0.00%
Elementis plc stock logo
ELMTY
Elementis
0.00%-1.32%-0.40%+3.46%+24.67%
Li & Fung Limited stock logo
LFUGY
Li & Fung
0.00%0.00%0.00%0.00%0.00%
Oxford Biomedica plc stock logo
OXBDF
Oxford Biomedica
0.00%+4.02%+9.68%+15.99%-50.77%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Clinigen Group plc stock logo
CLIGF
Clinigen Group
N/AN/AN/AN/AN/AN/AN/AN/A
Capstone Mining Corp. stock logo
CSFFF
Capstone Mining
N/AN/AN/AN/AN/AN/AN/AN/A
Elementis plc stock logo
ELMTY
Elementis
N/AN/AN/AN/AN/AN/AN/AN/A
Li & Fung Limited stock logo
LFUGY
Li & Fung
N/AN/AN/AN/AN/AN/AN/AN/A
Oxford Biomedica plc stock logo
OXBDF
Oxford Biomedica
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clinigen Group plc stock logo
CLIGF
Clinigen Group
N/AN/AN/AN/A
Capstone Mining Corp. stock logo
CSFFF
Capstone Mining
N/AN/AN/AN/A
Elementis plc stock logo
ELMTY
Elementis
N/AN/AN/AN/A
Li & Fung Limited stock logo
LFUGY
Li & Fung
N/AN/AN/AN/A
Oxford Biomedica plc stock logo
OXBDF
Oxford Biomedica
2.25
HoldN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clinigen Group plc stock logo
CLIGF
Clinigen Group
$704.71M1.51$1.43 per share5.60$4.52 per share1.77
Capstone Mining Corp. stock logo
CSFFF
Capstone Mining
$1.35B0.00N/AN/A$4.40 per share0.00
Elementis plc stock logo
ELMTY
Elementis
$713.40M1.54$0.82 per share9.15$5.77 per share1.30
Li & Fung Limited stock logo
LFUGY
Li & Fung
$12.70B0.08$0.05 per share4.72$0.44 per share0.51
Oxford Biomedica plc stock logo
OXBDF
Oxford Biomedica
$173.19M1.57N/AN/A$3.03 per share0.93

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clinigen Group plc stock logo
CLIGF
Clinigen Group
$40.78MN/A0.00N/AN/AN/AN/AN/A
Capstone Mining Corp. stock logo
CSFFF
Capstone Mining
-$101.67M-$0.150.00N/AN/A-7.56%-0.28%-0.15%N/A
Elementis plc stock logo
ELMTY
Elementis
$26.50MN/A0.0011.87N/AN/AN/AN/AN/A
Li & Fung Limited stock logo
LFUGY
Li & Fung
$35.14MN/A0.00N/AN/AN/AN/AN/A
Oxford Biomedica plc stock logo
OXBDF
Oxford Biomedica
-$48.43MN/A0.00N/AN/AN/AN/AN/AN/A

Latest ELMTY, CSFFF, CLIGF, LFUGY, and OXBDF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/22/2024Q4 2023
Capstone Mining Corp. stock logo
CSFFF
Capstone Mining
N/A$0.02+$0.02$0.06N/A$353.70 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Clinigen Group plc stock logo
CLIGF
Clinigen Group
N/AN/AN/AN/AN/A
Capstone Mining Corp. stock logo
CSFFF
Capstone Mining
N/AN/AN/AN/AN/A
Elementis plc stock logo
ELMTY
Elementis
N/AN/AN/AN/AN/A
Li & Fung Limited stock logo
LFUGY
Li & Fung
N/AN/AN/AN/AN/A
Oxford Biomedica plc stock logo
OXBDF
Oxford Biomedica
N/AN/AN/AN/AN/A

Latest ELMTY, CSFFF, CLIGF, LFUGY, and OXBDF Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2024
Elementis plc stock logo
ELMTY
Elementis
$0.07175/2/20245/3/20246/17/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clinigen Group plc stock logo
CLIGF
Clinigen Group
N/AN/AN/A
Capstone Mining Corp. stock logo
CSFFF
Capstone Mining
0.32
1.13
0.78
Elementis plc stock logo
ELMTY
Elementis
0.31
2.20
1.17
Li & Fung Limited stock logo
LFUGY
Li & Fung
N/AN/AN/A
Oxford Biomedica plc stock logo
OXBDF
Oxford Biomedica
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Clinigen Group plc stock logo
CLIGF
Clinigen Group
N/A
Capstone Mining Corp. stock logo
CSFFF
Capstone Mining
0.60%
Elementis plc stock logo
ELMTY
Elementis
N/A
Li & Fung Limited stock logo
LFUGY
Li & Fung
N/A
Oxford Biomedica plc stock logo
OXBDF
Oxford Biomedica
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Clinigen Group plc stock logo
CLIGF
Clinigen Group
1,069133.03 millionN/ANot Optionable
Capstone Mining Corp. stock logo
CSFFF
Capstone Mining
1,049753.41 millionN/ANot Optionable
Elementis plc stock logo
ELMTY
Elementis
1,281146.96 millionN/ANot Optionable
Li & Fung Limited stock logo
LFUGY
Li & Fung
16,8404.27 billionN/ANot Optionable
Oxford Biomedica plc stock logo
OXBDF
Oxford Biomedica
89196.26 millionN/ANot Optionable

ELMTY, CSFFF, CLIGF, LFUGY, and OXBDF Headlines

SourceHeadline
Oxford BioMedica PLCOxford BioMedica PLC
barrons.com - April 20 at 3:44 PM
Oxford Biomedica Insiders Placed Bullish Bets Worth UK£415.3kOxford Biomedica Insiders Placed Bullish Bets Worth UK£415.3k
finance.yahoo.com - March 30 at 10:23 AM
Oxford BioMedica sees highest patent filings and grants during December in Q4 2023Oxford BioMedica sees highest patent filings and grants during December in Q4 2023
pharmaceutical-technology.com - February 27 at 10:48 AM
Oxford BioMedica PLC (OXB)Oxford BioMedica PLC (OXB)
investing.com - January 23 at 11:53 PM
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturingOxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing
finance.yahoo.com - January 23 at 8:52 AM
Oxford Biomedica acquires ABL EuropeOxford Biomedica acquires ABL Europe
bioprocessintl.com - December 8 at 1:31 PM
Oxford BioMedica posts optimistic outlook on uptick in contract valueOxford BioMedica posts optimistic outlook on uptick in contract value
shareprices.com - December 7 at 6:54 PM
Oxford Biomedica strikes €15M deal to acquire French CDMO ABL EuropeOxford Biomedica strikes €15M deal to acquire French CDMO ABL Europe
fiercepharma.com - December 5 at 1:45 PM
Oxford Biomedica signs agreement to acquire ABL Europe from Institut MérieuxOxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux
poandpo.com - December 5 at 8:45 AM
Oxford BioMedica PLC OXOAOxford BioMedica PLC OXOA
morningstar.com - November 5 at 12:41 AM
Analysts Just Slashed Their Oxford Biomedica plc (LON:OXB) EPS NumbersAnalysts Just Slashed Their Oxford Biomedica plc (LON:OXB) EPS Numbers
finance.yahoo.com - September 25 at 4:56 AM
Oxford BioMedica shares boom as manufacturer expands complex cancer therapiesOxford BioMedica shares boom as manufacturer expands complex cancer therapies
msn.com - September 21 at 1:16 PM
Oxford BioMedica shares up, in talks to buy ABL Europe but loss widensOxford BioMedica shares up, in talks to buy ABL Europe but loss widens
lse.co.uk - September 20 at 8:20 AM
Oxford Biomedica stock soars on rosy forecast, talks to buy ABL EuropeOxford Biomedica stock soars on rosy forecast, talks to buy ABL Europe
msn.com - September 20 at 8:20 AM
Oxford BioMedica Shares Rise on Transformational Deal Talks, Revenue Growth ExpectationOxford BioMedica Shares Rise on Transformational Deal Talks, Revenue Growth Expectation
marketwatch.com - September 20 at 8:20 AM
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformationOxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
finance.yahoo.com - September 20 at 8:20 AM
Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® PlatformKyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform
finance.yahoo.com - September 20 at 8:20 AM
Oxford 250 history: The second decadeOxford 250 history: The second decade
sunjournal.com - September 10 at 3:32 PM
Oxford Biomedica to host webinar showcasing the TetraVecta™ systemOxford Biomedica to host webinar showcasing the TetraVecta™ system
finance.yahoo.com - September 7 at 8:04 AM
Oxford scientists find no evidence to suggest Facebook not good for wellbeingOxford scientists find no evidence to suggest Facebook not good for wellbeing
independent.co.uk - August 23 at 2:53 AM
Letchworth man jailed for Oxford BioMedica blackmailLetchworth man jailed for Oxford BioMedica 'blackmail'
readingchronicle.co.uk - July 11 at 6:17 PM
Oxford BioMedica company blackmailed for £300k by analystOxford BioMedica company 'blackmailed' for £300k by analyst
oxfordmail.co.uk - July 11 at 1:17 PM
Oxford BioMedica company blackmailed out of £300kOxford BioMedica company 'blackmailed' out of £300k
thisisoxfordshire.co.uk - July 11 at 8:16 AM
Oxford Biomedica (LON:OXB) shareholders have endured a 50% loss from investing in the stock five years agoOxford Biomedica (LON:OXB) shareholders have endured a 50% loss from investing in the stock five years ago
finance.yahoo.com - July 10 at 6:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Clinigen Group logo

Clinigen Group

OTCMKTS:CLIGF
Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Capstone Mining logo

Capstone Mining

OTCMKTS:CSFFF
Capstone Mining Corp. engages in the exploration and production of base metals in the United States, Mexico, Canada, and Chile. The company explores for copper, molybdenum, silver, zinc, lead, iron, and gold deposits. It holds interests in the Pinto Valley, an open pit copper mine located in Arizona, the United States; and the Cozamin, a copper-silver underground mine located in the state of Zacatecas, Mexico. The company also owns a 100% interest in copper-iron-gold Santo Domingo development project in Region III, Chile. The company was formerly known as Capstone Gold Corp. and changed its name to Capstone Mining Corp. in February 2006. The company is headquartered in Vancouver, Canada.
Elementis logo

Elementis

OTCMKTS:ELMTY
Elementis plc operates as a specialty chemical company in the United Kingdom, rest of Europe, North America, and internationally. It operates in two segments, Performance Specialties and Personal Care. The Performance Specialties segment engages in the production of rheological modifiers and additives for decorative and industrial coatings; and production and supply of talc for use in plastics, coatings, technical ceramics, and paper sectors. The Personal Care segment provides rheological modifiers and compounded products, including active ingredients for antiperspirants (AP) deodorants for personal care manufacturers. The company offers personal care products for antiperspirants, color cosmetics, and skin care applications; and performance specialties products for architectural coatings, adhesives, sealants and construction additives, and talc applications. Elementis plc was founded in 1844 and is headquartered in London, the United Kingdom.
Li & Fung logo

Li & Fung

OTCMKTS:LFUGY
Li & Fung Limited, an investment holding company, engages in managing the supply chain for retailers and brands worldwide. The company operates through two segments, Services and Products. The Services segment provides supply chain solutions, including product design, raw materials procurement, production and quality control, warehouse management, and last-mile delivery to retail stores or end-consumers in footwear and apparel, fast-moving consumer goods, food and beverage, and healthcare industries. The Products segment is involved in the onshore wholesale business. The company also engages in the distribution of fireworks. In addition, the company provides design and marketing, export trading, transportation, sample production, management and consultancy, sourcing, management support, commission agent, logistics, trade-related credit, accounting, freight forwarding, packaging, storage and warehousing, and customs brokerage services. Further, it designs, sources, and delivers apparel, accessories, and household items. The company serves specialty stores, department stores, big box retailers, e-commerce companies, hypermarkets, off-price retailers, and clubs. It operates through a network of approximately 230 offices and 270 distribution centers. Li & Fung Limited was founded in 1906 and is headquartered in Kowloon, Hong Kong.
Oxford Biomedica logo

Oxford Biomedica

OTCMKTS:OXBDF
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.